Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-22-expressing Saccharomyces boulardii
- Development stage
- Preclinical
- Lead developer
- Huashan Hospital
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
interleukin-22-expressing Saccharomyces boulardii is a genetically engineered live biotherapeutic product (LBP) developed by researchers at Huashan Hospital and Fudan University. It utilizes the probiotic yeast *Saccharomyces boulardii* as a delivery vehicle to constitutively express and secrete human interleukin-22 (IL-22) directly into the intestinal lumen. IL-22 is a cytokine that plays a pivotal role in mucosal immunity and tissue repair by binding to the IL-22 receptor on intestinal epithelial cells, thereby stimulating the production of antimicrobial peptides (such as Reg3γ) and promoting epithelial cell proliferation and goblet cell differentiation. This localized delivery approach is designed to treat *Clostridioides difficile* infection (CDI) and inflammatory bowel disease (IBD) by restoring the intestinal barrier and modulating the local immune response while minimizing potential systemic side effects associated with systemic cytokine administration.
- Other names
- IL-22-expressing S. boulardiiIL22-expressing S. boulardiiIL 22-expressing S. boulardiiIL-22-secreting Saccharomyces boulardiiIL22-secreting Saccharomyces boulardiiIL 22-secreting Saccharomyces boulardiiengineered Saccharomyces boulardii secreting IL-22
02
Targets
IL-22R (Interleukin 22 Receptor)
Beyond the preview
Go deeper on interleukin-22-expressing Saccharomyces boulardii.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-22-expressing Saccharomyces boulardii.